Lack of effect of verapamil and MDL 646, a cytoprotective PGE1 analogue on cyclosporin A nephrotoxicity in vitro.
Nephrotoxicity is the most troublesome side effect of cyclosporin A (CSA) therapy. In vitro studies have shown that verapamil and PGE analogues can protect human and rat kidney allografts and murine pancreatic B cells from CSA cytotoxicity. The LLC-PK.1 pig kidney cell line has recently been shown to be a use-ful in vitro model system for studying CSA nephrotoxicity. We have adopted the MTT assay to assess the effects of CSA on LCC-PK.1 cell growth and have examined the effects of verapamil and MDL 646, a cyto-protective PGE1 analogue, on CSA nephrotoxicity. The results show that neither compound prevents the cytotoxic effects of CSA on kidney cells.
Hall
T J
TJ
Merrell Dow Research Institute, Strasbourg, France.
Heckel
C
C
D000527:Alprostadil / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D002417:Cattle; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003524:Cyclosporins / Q000009:adverse effects; D007674:Kidney Diseases / Q000139:chemically induced* / Q000517:prevention & control; D011459:Prostaglandins E, Synthetic; D013552:Swine; D014700:Verapamil / Q000494:pharmacology*
D000897:Anti-Ulcer Agents; D003524:Cyclosporins; D011459:Prostaglandins E, Synthetic; D014700:Verapamil; D000527:Alprostadil; C036058:mexiprostil